Thursday, August 30, 2012
It is no secret that industry scientists often cannot
reproduce research published by others, but approaches to solving the problem
have been scarce and usually involve a would-be investor footing the bill for
additional studies. The newly launched Reproducibility Initiative has a
different approach and looks to put the onus on the originating academics to
pay for confirmatory experiments. Precise details regarding funding, standards
of reproducibility and potential conflicts of interest have yet to be worked
Fulmer, T. SciBX 5(34); doi:10.1038/scibx.2012.888
Published online Aug. 30, 2012
1. Begley, C.G. &
Ellis, L.M. Nature 483, 531-533 (2012)
2. Prinz, F. et al.
Nat. Rev. Drug Discov. 10, 712 (2011)
3. Osherovich, L. SciBX
AND INSTITUTIONS MENTIONED
Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif.
Atlas Venture, Boston, Mass.
(Xetra:BAYN), Leverkusen, Germany
Columbia University, New York, N.Y.
Dalhousie University, Halifax, Nova Scotia, Canada
Duke University, Durham, N.C.
figshare London, U.K.
InnoThink Center for Research in Biomedical Innovation, Indianapolis, Ind.
San Francisco, Calif.
PureTech Ventures, Boston, Mass.
Science Exchange, Palo Alto, Calif.
Stanford University School of Medicine, Palo Alto, Calif.
The University of Kansas Medical Center, Kansas City, Kan.
University of Virginia, Charlottesville, Va.
The University of Texas MD Anderson Cancer Center, Houston, Texas